Our lead program is azelaprag,
a potential first-in-class oral therapeutic
for obesity, followed by several earlier-stage metabolic programs
Program
Mechanism of Action
Route of administration
Indication
Status
Azelaprag
(BGE-105)
(BGE-105)
APJ agonist
Oral
IV
Obesity (tirzepatide co-administration)
Acute muscle atrophy
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
BGE-100
NLRP3 inhibitor
Oral
Neuroinflammation
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3
Discovery
Undisclosed metabolic
-
-
Discoverу
Lead Op
IND-enabling
Ph 1
Ph 2
Ph 3